{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T05:20:28Z","timestamp":1736659228242,"version":"3.32.0"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.intimp.2024.113790","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T17:42:26Z","timestamp":1734111746000},"page":"113790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Neoadjuvant immunotherapy and oncolytic virotherapy in HPV positive and HPV negative skin cancer: A comprehensive review"],"prefix":"10.1016","volume":"146","author":[{"given":"Ali","family":"Salimi Asl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Davari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atousa","family":"Ghorbani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narjes","family":"Seddighi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimia","family":"Arabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1679-1068","authenticated-orcid":false,"given":"Ehsan","family":"Saburi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2024.113790_b0005","first-page":"231","article-title":"Artificial Intelligence in Skin Cancer: A Literature Review from Diagnosis to Prevention and Beyond","volume":"2","author":"Ghorbani","year":"2023","journal-title":"Int J Bioinforma Intell Comput."},{"issue":"9","key":"10.1016\/j.intimp.2024.113790_b0010","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.3390\/jcm9092868","article-title":"Current and future trends in molecular biomarkers for diagnostic, prognostic, and predictive purposes in non-melanoma skin cancer","volume":"9","author":"Nikolouzakis","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.intimp.2024.113790_b0015","article-title":"When to suspect a non-melanoma skin cancer","volume":"368","author":"Smith","year":"2020","journal-title":"BMJ"},{"issue":"17","key":"10.1016\/j.intimp.2024.113790_b0020","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.3390\/cancers15174201","article-title":"Lymph Node Metastases from Non-Melanoma Skin Cancer of the Head and Neck","volume":"15","author":"Civantos","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.intimp.2024.113790_b0025","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7181\/acfs.2020.00262","article-title":"Basal cell carcinoma and squamous cell carcinoma in a single tumor in the anterior auricular area","volume":"21","author":"Lee","year":"2020","journal-title":"Arch Craniofacial Surg."},{"issue":"12","key":"10.1016\/j.intimp.2024.113790_b0030","doi-asserted-by":"crossref","first-page":"8925","DOI":"10.1002\/jcp.29737","article-title":"Probiotics with ameliorating effects on the severity of skin inflammation in psoriasis: Evidence from experimental and clinical studies","volume":"235","author":"Atabati","year":"2020","journal-title":"J Cell Physiol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113790_b0035","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1002\/onco.13593","article-title":"The Impact of Human Papillomavirus Infection on Skin Cancer: A Population\u2010Based Cohort Study","volume":"26","author":"Chen","year":"2021","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.intimp.2024.113790_b0040","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jaad.2017.08.059","article-title":"Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging","volume":"78","author":"Que","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2024.113790_b0045","article-title":"Papillomaviruses and cancer: commonalities and differences in HPV carcinogenesis at different sites of the body","volume":"1\u20139","author":"Egawa","year":"2023","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.113790_b0050","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.canlet.2019.11.039","article-title":"Human papillomavirus vaccine against cervical cancer: Opportunity and challenge","volume":"471","author":"Wang","year":"2020","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.intimp.2024.113790_b0055","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/ijc.33683","article-title":"Transcription of human papillomaviruses in nonmelanoma skin cancers of the immunosuppressed","volume":"149","author":"Arroyo M\u00fchr","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2024.113790_b0060","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1002\/ijc.30697","article-title":"Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16\u2010driven oropharyngeal squamous cell carcinoma","volume":"140","author":"Holzinger","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2024.113790_b0065","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/cup.13473","article-title":"Mucosal human papillomavirus detection and TP53 immunohistochemical expression in non\u2010melanoma skin cancer in Tunisian patients","volume":"46","author":"Ben Ayed","year":"2019","journal-title":"J. Cutan. Pathol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113790_b0070","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/msphere.00398-20","article-title":"Transforming properties of beta-3 human papillomavirus E6 and E7 proteins","volume":"5","author":"Minoni","year":"2020","journal-title":"Msphere."},{"issue":"02","key":"10.1016\/j.intimp.2024.113790_b0075","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/JD9.0000000000000087","article-title":"Beta human papillomavirus and merkel cell polyomavirus in skin neoplasms","volume":"3","author":"Lv","year":"2020","journal-title":"Int J Dermatology Venereol."},{"key":"10.1016\/j.intimp.2024.113790_b0080","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejca.2019.11.015","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment\u2013Update 2019","volume":"126","author":"Garbe","year":"2020","journal-title":"Eur J Cancer."},{"issue":"3","key":"10.1016\/j.intimp.2024.113790_b0085","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/jamadermatol.2018.4219","article-title":"Nationwide incidence of metastatic cutaneous squamous cell carcinoma in England","volume":"155","author":"Venables","year":"2019","journal-title":"JAMA Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113790_b0090","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10067-011-1878-z","article-title":"The initial presentation of systemic lupus erythematosis with aplastic anemia successfully treated with rituximab","volume":"31","author":"Alishiri","year":"2012","journal-title":"Clin Rheumatol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113790_b0095","first-page":"228","article-title":"Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside","volume":"8","author":"Saburi","year":"2017","journal-title":"Caspian J Intern Med."},{"issue":"6","key":"10.1016\/j.intimp.2024.113790_b0100","first-page":"1372","article-title":"Is \u03b1-N-acetylgalactosaminidase the key to curing cancer? A mini-review and hypothesis","volume":"22","author":"Saburi","year":"2017","journal-title":"J BUON."},{"key":"10.1016\/j.intimp.2024.113790_b0105","first-page":"10","article-title":"Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: a global-scale, cross-sectional, large-sample informatics study","author":"Guo","year":"2024","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.intimp.2024.113790_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118492","article-title":"Cell cytotoxicity, immunostimulatory and antitumor effects of lipid content of liposomal delivery platforms in cancer immunotherapies. A comprehensive in-vivo and in-vitro study","volume":"567","author":"Nikpoor","year":"2019","journal-title":"Int J Pharm."},{"issue":"9","key":"10.1016\/j.intimp.2024.113790_b0115","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy","volume":"41","author":"Topalian","year":"2023","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.intimp.2024.113790_b0120","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3322\/caac.21818","article-title":"Immunosurveillance in clinical cancer management","volume":"74","author":"Kroemer","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2024.113790_b0125","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.addr.2020.05.011","article-title":"Nanoparticles for topical drug delivery: Potential for skin cancer treatment","volume":"153","author":"Krishnan","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8","key":"10.1016\/j.intimp.2024.113790_b0130","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1111\/ajt.14238","article-title":"Chemotherapy and transplantation: the role of immunosuppression in malignancy and a review of antineoplastic agents in solid organ transplant recipients","volume":"17","author":"Krisl","year":"2017","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.intimp.2024.113790_b0135","first-page":"22","article-title":"Dermoscopy, confocal microscopy and other non-invasive tools for the diagnosis of non-melanoma skin cancers and other skin conditions","volume":"97","author":"Malvehy","year":"2017","journal-title":"Acta Derm. Venereol."},{"issue":"15","key":"10.1016\/j.intimp.2024.113790_b0140","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.3390\/jcm11154494","article-title":"The immunohistochemical assessment of neoangiogenesis factors in squamous cell carcinomas and their precursors in the skin","volume":"11","author":"Daneluzzi","year":"2022","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.intimp.2024.113790_b0145","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.3390\/cancers15061709","article-title":"Prevention and Treatment of HPV-Induced Skin Tumors","volume":"15","author":"Hasche","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0150","doi-asserted-by":"crossref","first-page":"9268","DOI":"10.1038\/s41598-020-66065-y","article-title":"Claudin expression profile in flat wart and cutaneous squamous cell carcinoma in epidermodysplasia verruciformis","volume":"10","author":"da Cruz Silva","year":"2020","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.intimp.2024.113790_b0155","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/biomedicines9020171","article-title":"Cutaneous squamous cell carcinoma: from pathophysiology to novel therapeutic approaches","volume":"9","author":"Fania","year":"2021","journal-title":"Biomedicines."},{"key":"10.1016\/j.intimp.2024.113790_b0160","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5701639","article-title":"The role of beta HPV types and HPV-associated inflammatory processes in cutaneous squamous cell carcinoma","volume":"2020","author":"Tampa","year":"2020","journal-title":"J. Immunol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0165","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/exd.14183","article-title":"Matrix metalloproteinases in keratinocyte carcinomas","volume":"30","author":"Riihil\u00e4","year":"2021","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.intimp.2024.113790_b0170","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.virol.2018.09.006","article-title":"High prevalence of Gammapapillomaviruses (Gamma-PVs) in pre-malignant cutaneous lesions of immunocompetent individuals using a new broad-spectrum primer system, and identification of HPV210, a novel Gamma-PV type","volume":"525","author":"Bolatti","year":"2018","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.intimp.2024.113790_b0175","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/CCO.0000000000000359","article-title":"Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence?","volume":"29","author":"Ribero","year":"2017","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.intimp.2024.113790_b0180","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s40265-020-01302-2","article-title":"Cemiplimab: a review in advanced cutaneous squamous cell carcinoma","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.intimp.2024.113790_b0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207019","article-title":"Correlation of Vascular Endothelial Growth Factor subtypes and their receptors with melanoma progression: A next-generation Tissue Microarray (ngTMA) automated analysis","volume":"13","author":"Seyed Jafari","year":"2018","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.intimp.2024.113790_b0190","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.intimp.2024.113790_b0195","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.intimp.2024.113790_b0200","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nrclinonc.2016.30","article-title":"Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?","volume":"13","author":"Bernstein","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0205","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000773","article-title":"Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma","volume":"8","author":"Curti","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2024.113790_b0210","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/j.ijrobp.2023.06.1142","article-title":"Influence of Bacterial Metabolites on the Systemic Antitumor Immune Response after Radiation Therapy in Combination with Immune Checkpoint Inhibitors","volume":"117","author":"Felchle","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.intimp.2024.113790_b0215","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002485","article-title":"Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma","volume":"9","author":"Leidner","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0220","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1200\/JCO.20.00290","article-title":"Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma","volume":"39","author":"McBride","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.intimp.2024.113790_b0225","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-17-3427","article-title":"Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy","volume":"24","author":"Marciscano","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2024.113790_b0230","first-page":"234","article-title":"Oncolytic viruses for cancer therapy: barriers and recent advances","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2024.113790_b0235","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.3389\/fimmu.2019.01848","article-title":"Immune conversion of tumor microenvironment by oncolytic viruses: the protoparvovirus H-1PV case study","volume":"10","author":"Marchini","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1348-8643(16)30016-7","article-title":"Development of oncolytic virotherapy for the treatment of oral cancer\u2013At the waiting stage for clinical use","volume":"14","author":"Yura","year":"2017","journal-title":"Oral Sci Int."},{"key":"10.1016\/j.intimp.2024.113790_b0245","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3389\/fimmu.2018.00866","article-title":"Oncolytic viral therapy and the immune system: a double-edged sword against cancer","volume":"9","author":"Marelli","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0458-z","article-title":"Oncolytic virus immunotherapy: future prospects for oncology","volume":"6","author":"Raja","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2024.113790_b0255","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1008866","article-title":"Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy","volume":"4","author":"Pol","year":"2015","journal-title":"Oncoimmunology."},{"issue":"25","key":"10.1016\/j.intimp.2024.113790_b0260","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2024.113790_b0265","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1503032","article-title":"Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors","volume":"7","author":"Pol","year":"2018","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.intimp.2024.113790_b0270","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fonc.2020.00475","article-title":"Delivery and biosafety of oncolytic virotherapy","volume":"10","author":"Li","year":"2020","journal-title":"Front. Oncol."},{"issue":"17","key":"10.1016\/j.intimp.2024.113790_b0275","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113790_b0280","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.intimp.2024.113790_b0285","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1158\/1078-0432.CCR-20-1170","article-title":"Talimogene laherparepvec and pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (MASTERKEY-232): a multicenter, phase 1b study","volume":"26","author":"Harrington","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2024.113790_b0290","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3390\/v13020196","article-title":"Antiviral activity of the G-quadruplex ligand TMPyP4 against herpes simplex virus-1","volume":"13","author":"Artusi","year":"2021","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.intimp.2024.113790_b0295","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.3390\/cells10061541","article-title":"Oncolytic herpes simplex virus-based therapies for cancer","volume":"10","author":"Aldrak","year":"2021","journal-title":"Cells."},{"issue":"19","key":"10.1016\/j.intimp.2024.113790_b0300","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-16-3232","article-title":"Phase I trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma","volume":"23","author":"Mell","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2024.113790_b0305","article-title":"Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity","volume":"3","author":"Hirvinen","year":"2016","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2024.113790_b0310","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3390\/cancers12061504","article-title":"Oncolytic adenoviruses: strategies for improved targeting and specificity","volume":"12","author":"Hajeri","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"19","key":"10.1016\/j.intimp.2024.113790_b0315","doi-asserted-by":"crossref","first-page":"7073","DOI":"10.3390\/ijms21197073","article-title":"Efficient delivery and replication of oncolytic virus for successful treatment of head and neck cancer","volume":"21","author":"Hamada","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2024.113790_b0320","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/mt.2016.66","article-title":"Randomized phase 2 trial of the oncolytic virus pelareorep (Reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma","volume":"24","author":"Noonan","year":"2016","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0325","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/mt.2015.156","article-title":"Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses","volume":"24","author":"Rajani","year":"2016","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.intimp.2024.113790_b0330","doi-asserted-by":"crossref","first-page":"T193","DOI":"10.1530\/ERC-21-0177","article-title":"The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment","volume":"28","author":"Spitzweg","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0335","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.apsb.2019.12.005","article-title":"Targeting uptake transporters for cancer imaging and treatment","volume":"10","author":"Zhang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.intimp.2024.113790_b0340","article-title":"Immunovirotherapy based on recombinant vesicular stomatitis virus: where are we?","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2024.113790_b0345","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/hed.23502","article-title":"Preclinical safety and activity of recombinant VSV\u2010IFN\u2010\u03b2 in an immunocompetent model of squamous cell carcinoma of the head and neck","volume":"36","author":"Kurisetty","year":"2014","journal-title":"Head Neck"},{"issue":"8","key":"10.1016\/j.intimp.2024.113790_b0350","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.ymthe.2017.05.006","article-title":"Oncolytic VSV primes differential responses to immuno-oncology therapy","volume":"25","author":"Durham","year":"2017","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2024.113790_b0355","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004307","article-title":"OrienX010, an oncolytic virus, in patients with unresectable stage IIIC\u2013IV melanoma: a phase Ib study","volume":"10","author":"Cui","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2024.113790_b0360","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1089\/hum.2018.107","article-title":"A phase 1 trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients","volume":"30","author":"Garcia","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.intimp.2024.113790_b0365","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2024.113790_b0370","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113790_b0375","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001681","article-title":"Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma","volume":"8","author":"Atkinson","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2024.113790_b0380","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2024.113790_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103679","article-title":"Immunotherapy for head and neck cancer: Present and future","volume":"174","author":"Fasano","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113790_b0390","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/JTO.0000000000000500","article-title":"Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation","volume":"10","author":"Chen","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2024.113790_b0395","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.oraloncology.2014.03.010","article-title":"HPV and head and neck cancers: state-of-the-science","volume":"50","author":"Fakhry","year":"2014","journal-title":"Oral Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2024.113790_b0400","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/lary.30389","article-title":"CD8+ and FoxP3+ T\u2010cell cellular density and spatial distribution after programmed death\u2010ligand 1 check point inhibition","volume":"133","author":"Curry","year":"2023","journal-title":"Laryngoscope"},{"issue":"7","key":"10.1016\/j.intimp.2024.113790_b0405","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/mc.23162","article-title":"Tumor immune microenvironment in head and neck cancers","volume":"59","author":"Chen","year":"2020","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.intimp.2024.113790_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105260","article-title":"All HPV-negative head and neck cancers are not the same: Analysis of the TCGA dataset reveals that anatomical sites have distinct mutation, transcriptome, hypoxia, and tumor microenvironment profiles","volume":"116","author":"Kim","year":"2021","journal-title":"Oral Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113790_b0415","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41416-018-0131-9","article-title":"Efficacy and safety of pembrolizumab in recurrent\/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012","volume":"119","author":"Mehra","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2024.113790_b0420","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2018.11.015","article-title":"Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with\u2265 25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy","volume":"107","author":"Zandberg","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"17","key":"10.1016\/j.intimp.2024.113790_b0425","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1158\/1078-0432.CCR-18-3944","article-title":"Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by prior cetuximab use","volume":"25","author":"Ferris","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.intimp.2024.113790_b0430","doi-asserted-by":"crossref","first-page":"9356","DOI":"10.3390\/app11199356","article-title":"Emerging oncogenic viruses in head and neck cancers from romanian patients","volume":"11","author":"Ursu","year":"2021","journal-title":"Appl. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2024.113790_b0435","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002568","article-title":"Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial","volume":"9","author":"Ferris","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0440","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113790_b0445","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3390\/cancers12040935","article-title":"Future challenges in cancer resistance to immunotherapy","volume":"12","author":"van Elsas","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.intimp.2024.113790_b0450","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.intimp.2024.113790_b0455","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.intimp.2024.113790_b0460","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S1470-2045(19)30407-3","article-title":"Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis","volume":"20","author":"Antonia","year":"2019","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113790_b0465","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.intimp.2024.113790_b0470","first-page":"323","article-title":". \u03b2 (2)-Microglobulin: Structure, Function and Significance","volume":"38","author":"Bernier","year":"1980","journal-title":"Vox Sang."},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0475","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1172\/JCI114984","article-title":"Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression","volume":"87","author":"d\u2019Urso","year":"1991","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0480","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.intimp.2024.113790_b0485","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.intimp.2024.113790_b0490","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"issue":"6349","key":"10.1016\/j.intimp.2024.113790_b0495","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.intimp.2024.113790_b0500","doi-asserted-by":"crossref","first-page":"15440","DOI":"10.1038\/ncomms15440","article-title":"Acquired IFNgamma resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions","volume":"8","author":"Sucker","year":"2017","journal-title":"Nat. Commun."},{"issue":"7749","key":"10.1016\/j.intimp.2024.113790_b0505","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.intimp.2024.113790_b0510","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non\u2013small cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0515","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2024.113790_b0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0780-0","article-title":"Secondary resistance to immunotherapy associated with \u03b2-catenin pathway activation or PTEN loss in metastatic melanoma","volume":"7","author":"Trujillo","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"21","key":"10.1016\/j.intimp.2024.113790_b0525","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.intimp.2024.113790_b0530","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2024.113790_b0535","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113790_b0540","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000891","article-title":"Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial","volume":"8","author":"Motzer","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2024.113790_b0545","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.intimp.2024.113790_b0550","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10088","key":"10.1016\/j.intimp.2024.113790_b0555","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"10272","key":"10.1016\/j.intimp.2024.113790_b0560","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.intimp.2024.113790_b0565","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0570","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2024.113790_b0575","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2024.113790_b0580","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113790_b0585","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0590","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/annonc\/mdx686","article-title":"Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy","volume":"29","author":"Rotte","year":"2018","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2024.113790_b0595","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0600","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000911","article-title":"Tim-3 finds its place in the cancer immunotherapy landscape","volume":"8","author":"Acharya","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0605","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG 3 (CD 223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.intimp.2024.113790_b0610","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2024.113790_b0615","doi-asserted-by":"crossref","first-page":"v611","DOI":"10.1093\/annonc\/mdx440.011","article-title":"Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti\u2013PD-1\/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched popu","volume":"28","author":"Ascierto","year":"2017","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113790_b0620","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0625","doi-asserted-by":"crossref","first-page":"12815","DOI":"10.1038\/s41598-020-69677-6","article-title":"Cutibacterium acnes regulates the epidermal barrier properties of HPV-KER human immortalized keratinocyte cultures","volume":"10","author":"Bolla","year":"2020","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.intimp.2024.113790_b0630","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3390\/cells13030266","article-title":"Optimization of Tissue Digestion Methods for Characterization of Photoaged Skin by Single Cell RNA Sequencing Reveals Preferential Enrichment of T Cell Subsets","volume":"13","author":"Clister","year":"2024","journal-title":"Cells."},{"key":"10.1016\/j.intimp.2024.113790_b0635","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.593901","article-title":"Skin viral infections: Host antiviral innate immunity and viral immune evasion","volume":"11","author":"Lei","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113790_b0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101714","article-title":"Lactobacillus gasseri LGV03 isolated from the cervico-vagina of HPV-cleared women modulates epithelial innate immune responses and suppresses the growth of HPV-positive human cervical cancer cells","volume":"35","author":"Gao","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.intimp.2024.113790_b0645","series-title":"Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022)","first-page":"1503","article-title":"The mechanism and prospects of HPV vaccine","author":"Zhang","year":"2023"},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0650","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tjog.2023.10.002","article-title":"Immunotherapy that leverages HPV-specific immune responses for precancer lesions of cervical cancer","volume":"63","author":"Kobayashi","year":"2024","journal-title":"Taiwan. J. Obstet. Gynecol."},{"key":"10.1016\/j.intimp.2024.113790_b0655","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1275270","article-title":"Deciphering the role of HPV-mediated metabolic regulation in shaping the tumor microenvironment and its implications for immunotherapy in HNSCC","volume":"14","author":"Gong","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113790_b0660","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29461","article-title":"The human papillomavirus late life cycle and links to keratinocyte differentiation","volume":"96","author":"Kirk","year":"2024","journal-title":"J. Med. Virol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113790_b0665","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ijc.31027","article-title":"Immune evasion mechanisms of human papillomavirus: An update","volume":"142","author":"Steinbach","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2024.113790_b0670","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00432-024-05606-8","article-title":"An angiogenesis-associated gene-based signature predicting prognosis and immunotherapy efficacy of head and neck squamous cell carcinoma patients","volume":"150","author":"Chen","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2024.113790_b0675","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1038\/s41416-023-02186-1","article-title":"Preclinical models in head and neck squamous cell carcinoma","volume":"128","author":"Chaves","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0680","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-022-02846-x","article-title":"Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages","volume":"23","author":"Dong","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"3","key":"10.1016\/j.intimp.2024.113790_b0685","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41568-022-00531-9","article-title":"Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment","volume":"23","author":"Ruffin","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2024.113790_b0690","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s12032-023-02289-y","article-title":"Evaluation of regulatory T-cells in cancer immunotherapy: therapeutic relevance of immune checkpoint inhibition","volume":"41","author":"Singh","year":"2024","journal-title":"Med Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0695","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-023-02691-4","article-title":"Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma","volume":"42","author":"Okuyama","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2024.113790_b0700","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jid.2022.12.007","article-title":"Poly (I: C) treatment prevents skin tumor formation in the preclinical HPV8 transgenic mouse model","volume":"143","author":"Hufbauer","year":"2023","journal-title":"J, Invest. Dermatol."},{"unstructured":"Zottnick S. Assessment of methods to direct T cells toward a newly established HPV16 E6\/E7-dependent orthotopic tumor model in A2. DR1 mice. 2023.","key":"10.1016\/j.intimp.2024.113790_b0705"},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0710","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/mBio.03224-20","article-title":"Development of DNA vaccine targeting E6 and E7 proteins of human papillomavirus 16 (HPV16) and HPV18 for immunotherapy in combination with recombinant vaccinia boost and PD-1 antibody","volume":"12","author":"Peng","year":"2021","journal-title":"MBio"},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0715","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007960","article-title":"Peritumoral administration of immunomodulatory antibodies as a triple combination suppresses skin tumor growth without systemic toxicity","volume":"12","author":"Wright","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2024.113790_b0720","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.pvr.2019.04.002","article-title":"Genetic susceptibility to cervical neoplasia","volume":"7","author":"Brown","year":"2019","journal-title":"Papillomavirus Res."},{"issue":"8","key":"10.1016\/j.intimp.2024.113790_b0725","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006866","article-title":"Defining the genetic susceptibility to cervical neoplasia\u2014A genome-wide association study","volume":"13","author":"Leo","year":"2017","journal-title":"PLoS Genet."},{"issue":"6","key":"10.1016\/j.intimp.2024.113790_b0730","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1080\/21645515.2016.1177680","article-title":"HPV vaccination: Clinical potential, implementation challenges, and future directions","volume":"12","author":"Perkins","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"issue":"3","key":"10.1016\/j.intimp.2024.113790_b0735","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/1346-8138.16697","article-title":"Recent advances in cutaneous HPV infection","volume":"50","author":"Shimizu","year":"2023","journal-title":"J. Dermatol."},{"key":"10.1016\/j.intimp.2024.113790_b0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104348","article-title":"Development of a \u03b2-HPV vaccine: updates on an emerging frontier of skin cancer prevention","volume":"126","author":"Gupta","year":"2020","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.intimp.2024.113790_b0745","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pvr.2019.04.003","article-title":"HPV and skin carcinogenesis","volume":"7","author":"Tommasino","year":"2019","journal-title":"Papillomavirus Res."},{"issue":"6","key":"10.1016\/j.intimp.2024.113790_b0750","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131052","article-title":"Mutations in the 5\u2019NTR and the non-structural protein 3A of the coxsackievirus B3 selectively attenuate myocarditogenicity","volume":"10","author":"Massilamany","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.intimp.2024.113790_b0755","doi-asserted-by":"crossref","first-page":"e2104","DOI":"10.1002\/rmv.2104","article-title":"Beta human papillomaviruses infection and skin carcinogenesis","volume":"30","author":"Bandolin","year":"2020","journal-title":"Rev. Med. Virol."},{"issue":"9","key":"10.1016\/j.intimp.2024.113790_b0760","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3921","article-title":"Pityriasis lichenoides et varioliformis acuta triggered by human papillomavirus vaccine: a case report and literature review","volume":"101","author":"Jastrz\u0105b","year":"2021","journal-title":"Acta Derm. Venereol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113790_b0765","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3390\/vaccines12030228","article-title":"Unveiling the Therapeutic Horizon: HPV Vaccines and Their Impact on Cutaneous Diseases\u2014A Comprehensive Review","volume":"12","author":"\u0218andru","year":"2024","journal-title":"Vaccines."},{"issue":"4","key":"10.1016\/j.intimp.2024.113790_b0770","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3346\/jkms.2017.32.4.599","article-title":"Increased serum antibody titer against HPV-16 antigen in patients with Beh\u00e7et\u2019s disease","volume":"32","author":"Kim","year":"2017","journal-title":"J. Korean Med. Sci."},{"issue":"43","key":"10.1016\/j.intimp.2024.113790_b0775","doi-asserted-by":"crossref","first-page":"5653","DOI":"10.1038\/onc.2016.102","article-title":"Loss of Keratin 17 induces tissue-specific cytokine polarization and cellular differentiation in HPV16-driven cervical tumorigenesis in vivo","volume":"35","author":"Hobbs","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0780","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008206","article-title":"Stress keratin 17 enhances papillomavirus infection-induced disease by downregulating T cell recruitment","volume":"16","author":"Wang","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.intimp.2024.113790_b0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvr.2023.200263","article-title":"Is immunotherapy a potential game changer in managing human papillomavirus (HPV) infection and intraepithelial neoplasia?","volume":"16","author":"Stern","year":"2023","journal-title":"Tumour Virus Res."},{"issue":"12","key":"10.1016\/j.intimp.2024.113790_b0790","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2214225120","article-title":"Stress keratin 17 and estrogen support viral persistence and modulate the immune environment during cervicovaginal murine papillomavirus infection","volume":"120","author":"Wang","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.intimp.2024.113790_b0795","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.cell.2023.02.032","article-title":"A neutrophil response linked to tumor control in immunotherapy","volume":"186","author":"Gungabeesoon","year":"2023","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.intimp.2024.113790_b0800","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.cell.2023.03.005","article-title":"Cancer immunotherapy: T cells and neutrophils working together to attack cancers","volume":"186","author":"Ager","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0805","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2024.113790_b0810","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.cell.2023.03.007","article-title":"T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants","volume":"186","author":"Hirschhorn","year":"2023","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.intimp.2024.113790_b0815","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1039\/D1BM00138H","article-title":"A hybrid HPV capsid protein L1 with giant Mo-containing polyoxometalate improves the stability of virus-like particles and the anti-tumor effect of [Mo 154]","volume":"9","author":"Xue","year":"2021","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.intimp.2024.113790_b0820","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.virusres.2016.11.020","article-title":"Developments in L2-based human papillomavirus (HPV) vaccines","volume":"231","author":"Schellenbacher","year":"2017","journal-title":"Virus Res."},{"issue":"1","key":"10.1016\/j.intimp.2024.113790_b0825","doi-asserted-by":"crossref","first-page":"81","DOI":"10.56098\/ijvtpr.v2i1.28","article-title":"Receipt of HPV vaccine associated with increased prevalence of high-risk HPV infections","volume":"2","author":"DeLong","year":"2021","journal-title":"Int J Vaccine Theory, Pract Res."},{"issue":"12","key":"10.1016\/j.intimp.2024.113790_b0830","article-title":"Oropharyngeal carcinoma: A single institution study of 338 primaries with special reference to high-risk human papillomavirus-mediated carcinoma with aggressive behavior","volume":"216","author":"Alexiev","year":"2020","journal-title":"Pathol Pract."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924023129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924023129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T16:48:34Z","timestamp":1736614114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924023129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":166,"alternative-id":["S1567576924023129"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113790","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant immunotherapy and oncolytic virotherapy in HPV positive and HPV negative skin cancer: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113790"}}